Amalgamated Bank acquired a new stake in shares of Acceleron Pharma Inc (NASDAQ:XLRN) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 5,556 shares of the biopharmaceutical company’s stock, valued at approximately $242,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its position in Acceleron Pharma by 50.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,017 shares of the biopharmaceutical company’s stock valued at $401,000 after acquiring an additional 2,354 shares in the last quarter. Alliancebernstein L.P. boosted its position in Acceleron Pharma by 6.7% during the 3rd quarter. Alliancebernstein L.P. now owns 61,900 shares of the biopharmaceutical company’s stock valued at $3,543,000 after acquiring an additional 3,900 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Acceleron Pharma by 10.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 189,390 shares of the biopharmaceutical company’s stock valued at $10,839,000 after acquiring an additional 18,286 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Acceleron Pharma by 36.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 5,980 shares of the biopharmaceutical company’s stock valued at $343,000 after acquiring an additional 1,596 shares in the last quarter. Finally, BlackRock Inc. boosted its position in Acceleron Pharma by 3.4% during the 3rd quarter. BlackRock Inc. now owns 4,347,892 shares of the biopharmaceutical company’s stock valued at $248,830,000 after acquiring an additional 142,823 shares in the last quarter. Institutional investors own 86.13% of the company’s stock.

In related news, EVP John D. Quisel sold 3,622 shares of the business’s stock in a transaction that occurred on Tuesday, April 9th. The shares were sold at an average price of $44.64, for a total value of $161,686.08. Following the completion of the transaction, the executive vice president now directly owns 54,004 shares in the company, valued at approximately $2,410,738.56. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Corp /De/ Celgene acquired 706,206 shares of the firm’s stock in a transaction that occurred on Friday, January 18th. The stock was purchased at an average price of $43.00 per share, with a total value of $30,366,858.00. Following the completion of the acquisition, the insider now owns 6,824,685 shares in the company, valued at $293,461,455. The disclosure for this purchase can be found here. Over the last three months, insiders sold 23,730 shares of company stock worth $1,060,959. Insiders own 3.00% of the company’s stock.

XLRN has been the topic of several research reports. BidaskClub raised Acceleron Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, March 6th. ValuEngine raised Acceleron Pharma from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 4th. HC Wainwright reissued a “buy” rating and issued a $67.00 price target (down from $72.00) on shares of Acceleron Pharma in a research report on Thursday, February 28th. Finally, Cowen began coverage on Acceleron Pharma in a research report on Monday, February 25th. They issued an “outperform” rating and a $78.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Acceleron Pharma currently has a consensus rating of “Buy” and an average target price of $60.63.

Shares of XLRN opened at $42.50 on Tuesday. Acceleron Pharma Inc has a 52 week low of $32.53 and a 52 week high of $59.59. The company has a market capitalization of $2.21 billion, a PE ratio of -16.41 and a beta of 1.41.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.07). Acceleron Pharma had a negative return on equity of 36.63% and a negative net margin of 849.62%. The company had revenue of $3.80 million during the quarter, compared to the consensus estimate of $3.21 million. During the same period in the prior year, the firm earned ($0.62) earnings per share. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, research analysts predict that Acceleron Pharma Inc will post -2.21 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Amalgamated Bank Acquires Shares of 5,556 Acceleron Pharma Inc (XLRN)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2019/04/16/amalgamated-bank-acquires-shares-of-5556-acceleron-pharma-inc-xlrn.html.

About Acceleron Pharma

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Recommended Story: Purposes and Functions of the Federal Reserve

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.